Patients with resected stage IIIB-C or stage IV melanoma had better long-term outcomes with nivolumab vs ipilimumab.

On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...

Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer.

The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

Designation places Mount Sinai among top one percent of cancer centers nationwide Mount Sinai Tisch Cancer Hospital Mount ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

Muscle-invasive bladder cancer patients who are ineligible or refuse cisplatin chemotherapy see “dramatic” improvements in ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with nivolumab versus placebo in all randomized patients (HR 0.66, 95% CI 0.53-0.81) ...

Adjuvant nivolumab (Opdivo) continued to show benefits in disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) who underwent radical surgery, ...